Literature DB >> 30803199

Economic Burden of Head and Neck Cancer Treatment in North India

Akashdeep Singh Chauhan1, Shankar Prinja, Sushmita Ghoshal, Roshan Verma.   

Abstract

Background: The rising cost of cancer treatment has imposed a huge financial burden on the affected households, leading to catastrophic outcomes and impoverishment. The present study was designed to estimate the economic burden incurred by households for the treatment of head and neck cancer (HNC) in India.
Methods: The present study was undertaken in a large public sector tertiary care hospital of North India. A total of 159 patients were recruited at time of their first registration in the department of Radiation Oncology, and were followed after completion of their treatment. Another 288 were recruited within one month after completion of treatment. Economic burden was assessed in terms of out of pocket (OOP) expenditure incurred, prevalence of catastrophic health expenditure and distress financing (borrowing or selling of assets) related to different modalities of cancer treatment.
Results: The average OOP expenditure incurred by a patient of HNC patient was INR 37, 845 (USD 563), which varied from INR 32,379 (USD 482) when a patient undergoes radiotherapy alone to INR 67,480 (USD 1,004) for surgery along with chemo-radiotherapy. Specifically, patients undergoing 2-DRT and IMRT alone had to spend INR 31,487 (USD 469) and INR 42,405 (USD 631) respectively. The prevalence of catastrophic health expenditure (CHE) and distress financing (DF) was 34% and 45% respectively. The odds of incurring both CHE and DF were found to be higher for patients in the lowest income quartile and for those in the younger age groups.
Conclusion: Cancer imposes significant economic burden on households. The existing public health system should be strengthened to reduce OOP expenditure incurred by patients. In addition, enhanced coverage of risk pooling mechanisms should be ensured. Creative Commons Attribution License

Entities:  

Keywords:  Head and neck cancer; radiotherapy; out of pocket expenditure; Catastrophic health expenditure

Mesh:

Year:  2019        PMID: 30803199     DOI: 10.31557/APJCP.2019.20.2.403

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  Out-of-Pocket, Catastrophic Health Expenditure and Distress Financing on Non-Communicable Diseases in India: A Systematic Review with Meta-Analysis.

Authors:  Anushikha Dhankhar; Ranjeeta Kumari; Yogesh A Bahurupi
Journal:  Asian Pac J Cancer Prev       Date:  2021-03-01

2.  Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India.

Authors:  Dimple Butani; Nidhi Gupta; Gaurav Jyani; Pankaj Bahuguna; Rakesh Kapoor; Shankar Prinja
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-11-27

3.  Economic Burden of Cancer Treatment in a Region in South India: A Cross Sectional Analytical Study.

Authors:  Pradeep Kumar Maurya; Sharan Murali; Venkatachalam Jayaseelan; Mahalakshmy Thulasingam; Jagadesan Pandjatcharam
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01

4.  Out-of-pocket costs associated with head and neck cancer treatment.

Authors:  Mohemmed N Khan; Katrina Hueniken; Mirko Manojlovic-Kolarski; Lawson Eng; Maryam Mirshams; Khaleeq Khan; Colleen Simpson; Michael Au; Geoffrey Liu; Wei Xu; Christopher J Longo; David P Goldstein; Jolie Ringash; Rosemary Martino; Aaron R Hansen; John R de Almeida
Journal:  Cancer Rep (Hoboken)       Date:  2021-08-24

5.  Financial toxicity and mental well-being of the oral cancer survivors residing in a developing country in the era of COVID 19 pandemic - A cross-sectional study.

Authors:  Abhinav Thaduri; Pankaj K Garg; Manu Malhotra; Mahendra Pal Singh; Dharma Ram Poonia; Madhu Priya; Amit Tyagi; Amit Kumar; Abhishek Bhardwaj; Bhinyaram Jat; Achyuth Panuganti; Kinjal Majumdar; Shahab Usmani
Journal:  Psychooncology       Date:  2022-09-08       Impact factor: 3.955

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.